Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

the PIONEER Consortium, Muhammad Imran Omar*, Steven MacLennan, Maria J. Ribal, Monique J. Roobol, Konstantinos Dimitropoulos, Thomas van den Broeck, Sara J. MacLennan, Susan Evans Axelsson, Giorgio Gandaglia, Peter Paul Willemse, Ken Mastris, John Butler Ransohoff, Zsuzsanna Devecseri, Thomas Abbott, Bertrand De Meulder, Anders Bjartell, Alex Asiimwe, James N’Dow, Emma SmithKarin Plass, Nicolas Mottet, Robert Shepherd, Lisa Moris, Michael Lardas, Nicola Fossati, Karl Pang, Riccardo Campi, Isabella Greco, Mauro Gacci, Sergio Serni, Ragnar Lonnerbro, Alberto Briganti, Daniele Crosti, Roberto Garzonio, Martina Faticoni, Chris Bangma, Eliza Roest, Arjan Breederland, Sebastiaan Remmers, Derya Tilki, Anssi Auvinen, Teemu Murtola, Tapio Visakorpi, Kirsi Talala, Teuvo Tammela, Aino Siltari, Mieke Van Hemelrijck, Katharina Beyer, Stephane Lejeune, Maxim Moinat

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups — health-care professionals and patients with prostate cancer — about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.

Original languageEnglish
Pages (from-to)494-501
Number of pages8
JournalNature Reviews Urology
Volume20
Issue number8
Early online date3 Apr 2023
DOIs
Publication statusPublished - Aug 2023

Bibliographical note

Funding Information:
PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein.

Publisher Copyright:
© 2023, Springer Nature Limited.

Fingerprint

Dive into the research topics of 'Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium'. Together they form a unique fingerprint.

Cite this